Welcome to the new Tamingthesru
Same great content - new look - improved search
SQuID Protocol for DKA: Impact on ED Length-of-Stay
With the advent of fast-acting subcutaneous insulin analogs over the past 20 years, multiple studies have demonstrated that subcutaneous insulin protocols for treatment for treatment of mild-to-moderate severity DKA are safe and cost-effective when compared to intravenous insulin infusion protocols in non-ICU settings. In the context of increasing ED and hospital crowding as well as limited ICU availability, this study aimed to evaluate the impact of a subcutaneous insulin (SQuID) protocol in the treatment of DKA on emergency department length-of-stay (EDLOS) and ICU admissions
Grand Rounds Recap 9.28.22
This week we had a tour de force of education goodness. We started off with Dr. Mullen presenting Morbidity and Mortality Conference. This was followed with an updated DKA QI/KT protocol developed by Dr. Shaw and Dr. Glenn. More great faculty Core Content was brought by Dr. Irankunda elucidating high pressure injection injuries. We wrapped up the day with some research nuggets with Dr. Freiermuth.
Hyperglycemia in the ED
In 2016, a total of 16 million ED visits were reported with diabetes listed as a diagnosis, with 224,000 of these being for hyperglycemic crisis (1). In this post, we will explore the evaluation and treatment of various hyperglycemic etiologies in the ED through a series of clinical scenarios.